Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study.

Community-acquired pneumonia Community-acquired respiratory viruses Epidemiology Molecular detection methods Post-pandemic Prospective study

Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
22 May 2024
Historique:
received: 08 02 2024
revised: 26 04 2024
accepted: 13 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 23 5 2024
Statut: aheadofprint

Résumé

Community-acquired pneumonia (CAP) is a major global cause of death and hospitalization. Bacteria or community-acquired viruses (CARVs) cause CAP. COVID-19 associated restrictions effectively reduced the circulation of CARVs. The aim of this study was to analyze the proportion of CARVs in adult patients with CAP from mid-2020 to mid-2023. Specifically, we aimed to compare the rate of influenza virus, SARS-CoV-2, and RSV detections in patients aged 18-59 years and ≥60 years. We analyze the proportion of 21 community-acquired respiratory viruses (CARVs) and three atypical bacteria (Bordetella pertussis, Legionella pneumophila, and Mycoplasma pneumoniae) in nasopharyngeal swab samples using molecular multiplex methods within the prospective, multicentre, multinational study of the German study Group CAPNETZ. We used stringent inclusion criteria throughout the study. We identified CARVs in 364/1,388 (26.2 %) patients. In detail, we detected SARS-CoV-2 in 210/1,388 (15.1 %), rhino-/enterovirus in 64/1,388 (4.6 %), influenza virus in 23/1,388 (1.6 %) and RSV in 17/1,388 (1.2 %) of all patients. We detected RSV and influenza more frequently in patients ≥60 years, especially in 22/23 compared to the previous season. None of the atypical bacteria were detected. Beginning in 2023, we demonstrate a re-emergence of CARVs in CAP patients. Effective vaccines or specific antiviral therapies for more than two thirds of the detected viral infections are currently available. High detection rates of vaccine-preventable viruses in older age groups support targeted vaccination campaigns.

Sections du résumé

BACKGROUND BACKGROUND
Community-acquired pneumonia (CAP) is a major global cause of death and hospitalization. Bacteria or community-acquired viruses (CARVs) cause CAP. COVID-19 associated restrictions effectively reduced the circulation of CARVs.
OBJECTIVES OBJECTIVE
The aim of this study was to analyze the proportion of CARVs in adult patients with CAP from mid-2020 to mid-2023. Specifically, we aimed to compare the rate of influenza virus, SARS-CoV-2, and RSV detections in patients aged 18-59 years and ≥60 years.
STUDY DESIGN METHODS
We analyze the proportion of 21 community-acquired respiratory viruses (CARVs) and three atypical bacteria (Bordetella pertussis, Legionella pneumophila, and Mycoplasma pneumoniae) in nasopharyngeal swab samples using molecular multiplex methods within the prospective, multicentre, multinational study of the German study Group CAPNETZ. We used stringent inclusion criteria throughout the study.
RESULTS RESULTS
We identified CARVs in 364/1,388 (26.2 %) patients. In detail, we detected SARS-CoV-2 in 210/1,388 (15.1 %), rhino-/enterovirus in 64/1,388 (4.6 %), influenza virus in 23/1,388 (1.6 %) and RSV in 17/1,388 (1.2 %) of all patients. We detected RSV and influenza more frequently in patients ≥60 years, especially in 22/23 compared to the previous season. None of the atypical bacteria were detected.
CONCLUSIONS CONCLUSIONS
Beginning in 2023, we demonstrate a re-emergence of CARVs in CAP patients. Effective vaccines or specific antiviral therapies for more than two thirds of the detected viral infections are currently available. High detection rates of vaccine-preventable viruses in older age groups support targeted vaccination campaigns.

Identifiants

DOI: 10.1016/j.jcv.2024.105694 PMID: 38781632
pubmed: 38781632
pii: S1386-6532(24)00056-8
doi: 10.1016/j.jcv.2024.105694
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105694

Investigateurs

A Fuchs (A)
M Engelmannn (M)
D Stolz (D)
W Bauer (W)
H C Mücke (HC)
N Suttorp (N)
M Witzenrath (M)
S Schmager (S)
B Schaaf (B)
J Kremling (J)
D Nickoleit-Bitzenberger (D)
H Azzaui (H)
M Hower (M)
F Hempel (F)
K Prebeg (K)
K Popkirova (K)
M Kolditz (M)
G Rohde (G)
C Bellinghausen (C)
A Grünewaldt (A)
M Panning (M)
T Welte (T)
T Fühner (T)
M Van't Klooster (M)
G Barten-Neiner (G)
W Kröner (W)
Ol Unruh (O)
N Adaskina (N)
F Eberherdt (F)
C Julius (C)
T Illig (T)
N Klopp (N)
M Pletz (M)
B T Schleenvoigt (BT)
C Forstner (C)
A Moeser (A)
J Ankert (J)
D Drömannn (D)
P Parschke (P)
K Franzen (K)
J Rupp (J)
N Käding (N)
F Waldeck (F)
C Spinner (C)
J Erber (J)
F Voit (F)
J Schneider (J)
D Heigener (D)
I Hering (I)
W Albrich (W)
M Seneghini (M)
F Rassouli (F)
S Baldesberger (S)
A Essig (A)
S Stenger (S)
M Wallner (M)
H Burgmann (H)
L Traby (L)
L Schubert (L)
R Chen (R)

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors have no conflict of interest to declare.

Auteurs

Theo Dähne (T)

Institute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Wolfgang Bauer (W)

Department of Emergency Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Andreas Essig (A)

Institute of Medical Microbiology and Hygiene, University Hospital of Ulm, Ulm, Germany.

Bernhard Schaaf (B)

Hospital Dortmund gGmbH, Dortmund, Germany.

Grit Barten-Neiner (G)

CAPNETZ STIFTUNG, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.

Christoph D Spinner (CD)

TUM School of Medicine and Health, Department of Clinical Medicine - Clinical Department for Internal Medicine II, University Medical Center, Technical University of Munich, Germany.

Mathias W Pletz (MW)

CAPNETZ STIFTUNG, Hannover, Germany; Institute of Infectious Diseases and Infection Control, Jena University Hospital / Friedrich-Schiller-University Jena, Jena, Germany.

Gernot Rohde (G)

CAPNETZ STIFTUNG, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany; Department of Respiratory Medicine, Medical Clinic I, Goethe University Hospital, Frankfurt, Main, Germany.

Jan Rupp (J)

CAPNETZ STIFTUNG, Hannover, Germany; Department of Infectious Diseases and Microbiology, University Hospital Schleswig-Holstein, Lübeck, Germany.

Martin Witzenrath (M)

CAPNETZ STIFTUNG, Hannover, Germany; Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Center for Lung Research (DZL), Berlin, Germany.

Marcus Panning (M)

Institute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: marcus.panning@uniklinik-freiburg.de.
III. Medical Clinic, University Hospital Augsburg, Germany.

Classifications MeSH